190 likes | 466 Views
ARV Program in Indonesia: Advantages, Challenges and the Way Forward. Dr. Endang Budi Hastuti National AIDS Program Ministry of Health of Republic of Indonesia. Outline Presentation. HIV/AIDS in Indonesia Overview of HIV/AIDS control system
E N D
ARV Program in Indonesia:Advantages, Challenges and the Way Forward Dr. Endang Budi Hastuti National AIDS Program Ministry of Health of Republic of Indonesia
Outline Presentation • HIV/AIDS in Indonesia • Overview of HIV/AIDS control system • ARV : financing, supply and distribution system • Advantages and challenges of current ARV supply chain management system • Future strategic plans in scaling up ARV program
TreatmentCascade 2005 - 2012 68% 73% 53% ART Coverage : 31002/178631 = 17.4% Estimation of PLWHA 2012 = 591.823 HIV Treatment Monthly Report, 2005-2012. MoH RI
ARV Hospitals • Since 2005 • In all provinces • Complete services • Government and private hospitals 2005 2015
ARV financing system • ARV is produced and procured since 2005 (locally and imported) • Fund source: national budget and GF-AIDS • The ARV budgeting is planned annually, integrated in national budget planning • The budget is managed by MoH: • Forecasting, planning, distribution NAP • Procurement process Directorate General of Pharmacy Service, MoH and VPP (GF) • MoH Indonesia is about to develop one gate policy for procurement
ARV financing system • Minister of Health Decree: ARV is fully subsidized by central government since 2005 • Budget allocation from national funding is increasing 26.09 13.51 3.48 1.64 2.3
ARV supply system • The ARV procurement is centalized, and involving MoH (NAP and Pharmacy), GF, Local and Global producers and National warehouse • ARV available: ZDV, TDF, FTC, NVP, EFV, LPV/r, d4T, ABC, ddI • The average cost for 1st line ARV treatment per patient per year 420 - 480 USD
Global Producer Global Fund Voluntary Pooled Procurement National Warehouse ARV Supply System MINISTRY OF HEALTH Purchase Order LOCAL SASWaiver , Tax and Duty Exemption & Custom Clearance IMPORT NAP Bidding Process PHARMACY Local Producer – Kimia Farma
ARV distribution system • ARV distribution system is centralized since 2005 • ARV decentralized distribution is started in 2011 and expanded gradually
ARV distribution system - Centralized (4A) Delivery (2) Confirmation (3A) DO (1) Monthly report HOSPITAL NAP NATIONAL WAREHOUSE 3 months stock (3B) DO (4B) Delivery NAP WAREHOUSE
ARV distribution system - Decentralized (4) Delivery (1) Monthly report (3) DO PROVINCIAL WAREHOUSE (2) Confirmation PHO 6 months stock HOSPITAL 3 months stock (5) Quarterly report (7) Delivery, quarterly (6) DO Quarterly NAP NATIONAL WAREHOUSE
Advantages of current ARV supply chain management system Centralized ARV distribution: • Central government can directly control the ARV distribution in ARV hospitals Decentralized ARV distribution: • simplify the route minimize ARV stock out in hospital • PHO has ownership in managing the ARV management • Involvement of the local CSO, to monitor the ARV management
Challenges of current ARV supply chain management system Centralized ARV distribution: • Geographic long route • More ARV hospitals, lack of human resource Decentralized ARV distribution: • Readiness of PHO, capacity of human resource • The existing logistic mechanism is vary among provinces (some are under disease program in PHO and some are under pharmacy program need strengthening of coordination)
Future strategic plans in scaling up ARV program • HIV testing acceleration: • Offering HIV test to pregnant women, TB patients, STI patients • Strengthening PITC implementation • Mobile clinic • HIV retesting for KAPs every 6 months • ART coverage acceleration: • Start ART • when CD4 count ≤ 350 • Regardless CD4 count for : pregnant women, TB-HIV patients, sero-discordant couple, KAPs, prisoners • Triple FDC • ART initiation at Primary Health Care